Shariati Hooman, Sanei Hamid, Pourmoghadas Ali, Salehizadeh Leila, Amirpour Afshin
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Interventional Cardiologist, Chamran Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2016 Dec 27;5:204. doi: 10.4103/2277-9175.196831. eCollection 2016.
The objective of the present study was to assess the major immediate outcomes of eptifibatide therapy during intracoronary stent implantation.
In an interventional study, patients undergoing percutaneous coronary intervention (PCI) were randomized into either the eptifibatide ( = 100) or the control ( = 107) group. In each group, demographic and clinical characteristics such as cardiac death, stent thrombosis (ST), myocardial infarction (MI), rates of target lesion and vessel revascularization, cerebral vascular accident (CVA), and emergency coronary artery bypass grafting (CABG) were recorded.
The overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; > 0.05 considered significant for all comparisons.
There were no statistical differences between the clinical outcomes of groups administered with single-dose intracoronary eptifibatide and control groups among patients undergoing PCI during stent implantation.
本研究的目的是评估冠状动脉内支架植入术中依替巴肽治疗的主要即时结果。
在一项干预性研究中，接受经皮冠状动脉介入治疗（PCI）的患者被随机分为依替巴肽组（n = 100）或对照组（n = 107）。记录每组患者的人口统计学和临床特征，如心源性死亡、支架血栓形成（ST）、心肌梗死（MI）、靶病变和靶血管血运重建率、脑血管意外（CVA）以及急诊冠状动脉旁路移植术（CABG）。
支架植入后24小时内，两组患者的死亡率、支架血栓形成（ST）、心肌梗死（MI）、靶病变血运重建（TLR）、靶血管血运重建（TVR）、CVA和急诊CABG等主要不良事件的总体发生率较低且相当；所有比较中P>0.05被认为无统计学意义。
在支架植入期间接受PCI的患者中，单剂量冠状动脉内给予依替巴肽的组与对照组的临床结果之间无统计学差异。
